ClinicalTrials.Veeva

Menu

A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers (FFCD-2205)

F

Federation Francophone de Cancerologie Digestive

Status

Enrolling

Conditions

Hepatic Leiomyosarcomas
Fibrolamellar Carcinoma
Hepatic Epithelioid Hemangioendothelioma
Hepatocholangiocarcinoma
Cholangiocarcinoma
Hepatic Angiosarcomas
Hepatoblastoma
Hepatic Neuroendocrine Carcinoma
Hepatic Cystadenoma
Hepatic Carcinosarcomas

Study type

Observational

Funder types

Other

Identifiers

NCT06541652
2023-A01517-38 (Registry Identifier)
CAPRIH COHORT

Details and patient eligibility

About

The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.

Full description

The aim is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences.

Enrollment

150 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18 years of age or older,
  • with histologically proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma
  • diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort
  • for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies.

Exclusion criteria

  • without social security
  • No access to tumor block

Trial contacts and locations

29

Loading...

Central trial contact

lila gaba

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems